Pharma Focus Asia
Klöckner Pentaplast - Pentapharm® alfoil® films

Tiziana Life Sciences Reveals Results of Study on Intranasal Anti-CD3 Foralumab in Multiple Sclerosis Patients, Highlighting PIRA Significance in Neurology Today®

Saturday, April 20, 2024

Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) recently announced a significant development regarding its lead candidate, foralumab, in a study highlighted by Neurology Today®, the official news source of the American Academy of Neurology.

The study, conducted by Dr. Tarun Singhal, reveals promising findings about foralumab's efficacy in reducing microglial activation in non-active secondary progressive multiple sclerosis (na-SPMS) patients with progression independent of relapse (PIRA). PIRA presents a significant challenge in MS treatment, with no approved therapies currently available. Dr. Singhal emphasizes the study's implications, suggesting foralumab's potential in addressing this elusive form of MS.

Dr. John Corboy, an authority in neurology, also highlights the importance of altering microglial activation, particularly considering the limited impact of existing treatments. He underscores foralumab's potential in this regard.

The study assesses the impact of intranasal foralumab on microglial activation in na-SPMS patients with PIRA, utilizing positron emission tomography (PET) imaging with [F-18]PBR06-PET. Encouragingly, the results demonstrate a qualitative reduction in microglial activation across multiple brain regions in a significant majority of patients after 3 and 6 months of treatment.

Presented at the Annual Meeting of the American Academy of Neurology, the study offers promising insights into foralumab's potential to mitigate PIRA and stabilize clinical progression in non-active secondary progressive MS. This marks a significant step forward in the quest for effective treatments for MS patients.

Foralumab, as the only fully human anti-CD3 monoclonal antibody, modulates T cell function to suppress inflammation, a crucial mechanism in MS and other inflammatory conditions. The ongoing Phase 2 trial of intranasal foralumab in non-active SPMS patients underscores its potential as a novel therapeutic approach for neuroinflammatory and neurodegenerative diseases.

 

Source: globenewswire.com

magazine-slider-imageBIOVIA from Molecule to MedicineMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopCPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024